Olaparib (Lynparza®) (1L maintenance of BRCA-mutated advanced OVCA)

Assessment Status Assessment process complete
Drug Olaparib
Brand Lynparza®
Indication For the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
Assessment Process
Rapid review commissioned 30/04/2019
Rapid review completed 09/05/2019
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 15/05/2019
Pre-submission consultation with Applicant 15/07/2019
Full submission received from Applicant 10/10/2019
Preliminary review sent to Applicant 08/01/2020
NCPE assessment re-commenced 24/01/2020
Factual accuracy sent to Applicant 09/03/2020
NCPE assessment re-commenced 13/03/2020
NCPE assessment completed 30/03/2020
NCPE assessment outcome The NCPE recommends that olaparib (Lynparza®) for this indication not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Technical Summary

Plain English Summary

The HSE has approved reimbursement following confidential price negotiations; December 2020